TrialFrontiers in immunology2025

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with

Gyeong Ho Baek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.